Skip to main content

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic’s accelerating transition from platform development to commercial product expansion and recurring revenue...

Continue reading

JZXN Announces Groundbreaking US$1 Billion Plan to Acquire 10,000 BTC from Strategic Investor, Strengthening Global Cryptocurrency Partnership

HANGZHOU, March 04, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN) (the “Company” or “JZXN”) today announced a transformative strategic agreement with a prominent global digital asset investor. Under the proposed landmark plan, the strategic investor will transfer 10,000 Bitcoins (BTC) to JZXN in exchange for equity consideration valued at approximately US$1 billion, while the two parties establish a deep, long-term strategic partnership to strengthen collaboration across the global cryptocurrency ecosystem. This definitive strategic plan represents a major milestone in JZXN’s digital asset expansion roadmap. The acquisition of 10,000 BTC will significantly enhance the Company’s digital asset treasury reserves, reinforce balance sheet strength, and elevate JZXN’s position within the global cryptocurrency market. The...

Continue reading

TransUnion to Present at the 2026 RBC Capital Markets Global Financial Institutions Conference

CHICAGO, March 04, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced that Chris Cartwright, President and CEO, and Todd Cello, Executive Vice President, Chief Financial Officer, will present at the RBC Capital Markets Global Financial Institutions Conference on Wednesday, March 11, 2026. The presentation is scheduled to begin at 9:40 a.m. CT (10:40 a.m. ET). A live webcast of the presentations will be made available on the TransUnion Investor Relations website at http://www.transunion.com/tru. A replay will also be available on the company’s website following the conclusion of the presentation. About TransUnion (NYSE: TRU) TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in...

Continue reading

Descartes Expands AI Innovation on Global Logistics Network with AI Agents for Freight Visibility

Over 720,000 AI-powered driver engagements accelerate network expansion, connecting 435,000+ more drivers in just months to improve freight tracking accuracy. LONDON and ATLANTA, March 04, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced expanded artificial intelligence (AI) capabilities on its multimodal Global Logistics Network (GLN) with the introduction of Descartes MacroPoint™ OpsForce, a suite of AI agents designed to automate freight visibility workflows, maintain tracking continuity and improve execution across complex, inter-enterprise supply chains. Built on the scale and real-time data of the GLN, OpsForce leverages trusted, clean and formatted network intelligence to power automated driver engagement, exception...

Continue reading

Information on the total number of voting rights and shares of 74Software share capital as of February 28, 2026

Press Release Information on the total number of voting rights and shares of 74Software share capital as of February 28, 2026 Paris, March 4, 2026 – In accordance with Articles L.233-8 II and R.225-73 I of the French Commercial Code (Code de Commerce) and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (RGAMF), 74Software hereby informs its shareholders that, as of February 28, 2026:Total number of shares is 29,746,194. Total number of theoretical voting rights is 41,275,436.It is calculated according to the total number of shares with voting rights, including those whose voting rights have been suspended, and is used to declare threshold crossing by shareholders in accordance with Article 223-11 of the RGAMF.Number of exercisable voting rights is 40,787,088.Disclaimer This document is a...

Continue reading

Ducommun to Participate in Sidoti Small Cap Conference

COSTA MESA, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) announced today that Suman Mookerji, the Company’s senior vice president and chief financial officer, and Christian Prezgay, senior director, financial planning and analysis and investor relations, will participate in the upcoming Sidoti Small Cap Conference on March 18, 2026. A general presentation will be held at 4:00p.m. Eastern, with one-on-one investor meetings scheduled throughout the day. Additional information will be posted on the Company’s website at www.ducommun.com when available, including a copy of any presentation material. A live webcast of the presentation can be accessed using this link. A replay of the webcast will be available on the Ducommun website at www.ducommun.com. Institutional investors...

Continue reading

FBS Global Regains Full Nasdaq Compliance; Minimum Bid Price Matter Resolved

Company’s Ordinary Shares Close Above $1.00 for Ten Consecutive Trading Days, Satisfying Nasdaq Listing Requirement Singapore, March 04, 2026 (GLOBE NEWSWIRE) — FBS Global Limited (Nasdaq: FBGL) (“FBS” or the “Company”), a green building contractor and interior fit-out specialist with more than 20 years of operating history, today announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on the Nasdaq Capital Market. On February 27, 2026, the Company received formal confirmation from The Nasdaq Stock Market LLC that, for the ten consecutive business days from February 12, 2026 through February 26, 2026, the closing bid price of the Company’s ordinary shares was at or above $1.00 per share. As a result, the previously disclosed minimum bid price deficiency...

Continue reading

WeRide to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 23, 2026

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD), a global leader in autonomous driving technology, today announced that it will release its unaudited financial results for the fourth quarter and full year 2025 on Monday, March 23, 2026, before the open of the U.S. markets. The Company’s management will host an earnings conference call at 8:00 A.M. U.S. Eastern Time on March 23, 2026 or 8:00 P.M. Hong Kong Time on the same day to discuss the results. Details for the conference call are as follows: Event Title: WeRide Inc. Fourth Quarter and Full Year 2025 Earnings Call English Registration Link: https://register-conf.media-server.com/register/BI98ad9a5da2d8418781930021448b277b Chinese Simultaneous Interpretation Registration Link (listen-only mode): https://register-conf.media-server.com/register/BI5cdaf73794244bef8f4e6c8a09f2a403 All...

Continue reading

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never leaves the client’s control Platform-as-a-service model designed to generate recurring revenue by licensing AI capabilities to biotech and pharmaceutical companies of all sizes — addressing a market where the top 20 pharma companies invested approximately $167 billion in R&D in 2024 but have only recently begun to deploy meaningful AI budgets KALA to serve as its own first deployment client, applying Researgency to its proprietary MSC-S biological datasets and KPI-012 clinical program before scaling to external biotech partners Exclusive worldwide license secured for the Researgency platform in the biotechnology field...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.